Request Your Free Trend Report Now:

"Top market strategies for today's pharma landscape"

The complexity of turning a new drug into a successful asset remains a hurdle even beyond the coveted FDA approval.

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.

included in this trendline:

• Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
• Hemophilia gene therapies are struggling on the market, even as innovation soars
• As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Offered Free by: PharmaVoice's and EVERSANA
See All Resources from: PharmaVoice's and EVERSANA